Nucleome Therapeutics

New appointment
#New appointment #Nucleome Therapeutics

Nucleome appoints Morrow as Chief Scientific Officer

Michelle Morrow has left her position at Avacta to join Nucleome Therapeutics as Chief Scientific Officer (CSO).  Morrow joins Nucleome with two decades of experience in drug discovery and development and executing R&D strategy across biotech and large pharma.   Prior to Avacta, Michelle was SVP, Head of invoX Therapeutics Innovation,… Read More

#Business & Investment #News